TR200801968T2 - HFSH sulu formülasyon. - Google Patents

HFSH sulu formülasyon.

Info

Publication number
TR200801968T2
TR200801968T2 TR2008/01968T TR200801968T TR200801968T2 TR 200801968 T2 TR200801968 T2 TR 200801968T2 TR 2008/01968 T TR2008/01968 T TR 2008/01968T TR 200801968 T TR200801968 T TR 200801968T TR 200801968 T2 TR200801968 T2 TR 200801968T2
Authority
TR
Turkey
Prior art keywords
hfsh
aqueous formulation
stabilized
longer period
time
Prior art date
Application number
TR2008/01968T
Other languages
English (en)
Inventor
Sung Jeh Hoon
Young Choi Suk
Original Assignee
Lg Life Sciences Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37899985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200801968(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd. filed Critical Lg Life Sciences Ltd.
Publication of TR200801968T2 publication Critical patent/TR200801968T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

hFSH'nin daha uzun bir süre boyunca faaliyet göstermesini sağlamak amacıyla stabilize edilen bir insan follikül uyarıcı hormonunun sulu bir formülasyonu sağlanmaktadır. Mevcut buluşa göre formülasyon daha uzun bir süre boyunca hFSH'nin faaliyet göstermesini sağlayabilen ve glisin, metiyonin ve non-iyonik bir yüzey aktif madde, tercihen polisorbat 20 içeren bir fosfat tamponu içerisinde stabilize edilen hFSH'den terapötik olarak etkili bir miktarda içeren sulu bir formülasyondur.
TR2008/01968T 2005-09-27 2006-09-25 HFSH sulu formülasyon. TR200801968T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020050089853A KR101105871B1 (ko) 2005-09-27 2005-09-27 인 난포자극호르몬의 안정한 용액 제형

Publications (1)

Publication Number Publication Date
TR200801968T2 true TR200801968T2 (tr) 2008-06-23

Family

ID=37899985

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2008/01968T TR200801968T2 (tr) 2005-09-27 2006-09-25 HFSH sulu formülasyon.

Country Status (18)

Country Link
US (2) US20110201554A1 (tr)
EP (1) EP1928413B1 (tr)
JP (1) JP5364374B2 (tr)
KR (1) KR101105871B1 (tr)
CN (1) CN101272764B (tr)
AR (1) AR056538A1 (tr)
AT (1) ATE466570T1 (tr)
AU (1) AU2006295570B2 (tr)
BR (1) BRPI0616300A2 (tr)
DE (1) DE602006014175D1 (tr)
ES (1) ES2345058T3 (tr)
GT (1) GT200600431A (tr)
PE (1) PE20070437A1 (tr)
RU (1) RU2407514C2 (tr)
SA (1) SA06270332B1 (tr)
TR (1) TR200801968T2 (tr)
TW (1) TW200735897A (tr)
WO (1) WO2007037607A1 (tr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8617568B2 (en) 2007-07-10 2013-12-31 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
EP2249869B1 (en) * 2008-02-08 2011-09-07 BioGeneriX AG Liquid formulation of fsh
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
CA2742659C (en) 2008-11-04 2016-09-27 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone
PL2451437T3 (pl) 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
RU2553375C2 (ru) * 2010-02-12 2015-06-10 Интас Биофармасьютикалс Лимитед Жидкий состав фолликулостимулирующего гормона
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
WO2015075743A1 (en) * 2013-11-12 2015-05-28 Cadila Healthcare Limited Formulation for gonadotropins
JP6723921B2 (ja) 2014-01-09 2020-07-15 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
CN105960249B (zh) 2014-01-09 2021-03-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
WO2020004368A1 (ja) * 2018-06-25 2020-01-02 Ｊｃｒファーマ株式会社 蛋白質含有水性液剤
CN115429751B (zh) * 2022-09-21 2023-11-17 景泽生物医药(合肥)股份有限公司 一种人重组卵泡刺激素注射剂及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
RU2062619C1 (ru) * 1994-02-08 1996-06-27 Курский сельскохозяйственный институт им.проф.И.И.Иванова Способ получения препарата фолликулостимулирующего гормона из аденогипофизов животных
WO1996029095A1 (en) * 1995-03-21 1996-09-26 Applied Research Systems Ars Holding N.V. Hcg liquid formulations
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
CN1309567A (zh) * 1998-07-23 2001-08-22 伊莱利利公司 Fsh和fsh变体制剂,产品和方法
JP4360758B2 (ja) * 1999-04-08 2009-11-11 ジェネンテック・インコーポレーテッド 逆の電荷のポリペプチド類をベースにした組成物
US7514239B2 (en) * 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
CA2422076A1 (en) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
JP5290489B2 (ja) * 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
EP1471891A4 (en) * 2002-02-08 2007-04-11 Alkermes Inc POLYMER BASED COMPOSITIONS WITH DELAYED RELEASE
US20050232899A1 (en) * 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
CN1195069C (zh) * 2002-11-28 2005-03-30 南京医科大学 人卵泡刺激素β亚基单克隆抗体的制备方法
CA2518903C (en) * 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
TW200640492A (en) * 2005-02-21 2006-12-01 Lg Life Sciences Ltd Sustained release composition of protein drug
MX2007015476A (es) * 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
EP2249869B1 (en) * 2008-02-08 2011-09-07 BioGeneriX AG Liquid formulation of fsh

Also Published As

Publication number Publication date
EP1928413A1 (en) 2008-06-11
EP1928413A4 (en) 2008-12-03
CN101272764B (zh) 2011-05-04
JP5364374B2 (ja) 2013-12-11
ES2345058T3 (es) 2010-09-14
EP1928413B1 (en) 2010-05-05
CN101272764A (zh) 2008-09-24
US20110201554A1 (en) 2011-08-18
BRPI0616300A2 (pt) 2011-06-14
GT200600431A (es) 2007-08-28
AR056538A1 (es) 2007-10-10
TW200735897A (en) 2007-10-01
RU2008111632A (ru) 2009-10-10
WO2007037607A1 (en) 2007-04-05
AU2006295570A1 (en) 2007-04-05
SA06270332B1 (ar) 2011-01-15
RU2407514C2 (ru) 2010-12-27
KR101105871B1 (ko) 2012-01-16
AU2006295570B2 (en) 2012-08-30
US20160243242A1 (en) 2016-08-25
ATE466570T1 (de) 2010-05-15
KR20070035232A (ko) 2007-03-30
PE20070437A1 (es) 2007-04-26
JP2009509953A (ja) 2009-03-12
DE602006014175D1 (de) 2010-06-17

Similar Documents

Publication Publication Date Title
TR200801968T2 (tr) HFSH sulu formülasyon.
TNSN07020A1 (en) Her2 antibody composition
PE20050586A1 (es) Preparacion farmaceutica que comprende un anticuerpo contra el receptor egfr
BRPI0411241A (pt) agentes terapêuticos úteis para o tratamento de dor
BRPI0813699A2 (pt) Formulações de proteína de fusão glp-1-fc
PL366579A1 (en) Treatment of nail infections with no
BR0307702A (pt) Formulações de solução contendo anticorpo
TNSN08511A1 (en) Lyophilized formulations of anti-egfr antibodies
CY1113834T1 (el) Υγρο παρασκευασμα αυξητικης ορμονης
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
ATE322878T1 (de) Biotin enthaltende galenische formulierung
GT200500111A (es) Acido 2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor de la cinasa ikb
EA200900095A1 (ru) Лекарственные формы бифосфонатов для ингаляции и способы их применения
DE60307665D1 (de) Haarbehandlungszusammensetzungen mit xanthin und alpha-hydroxysäure
DE50307276D1 (de) Haarshampoo für feines und fettiges Haar
PE20050665A1 (es) ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
TW200505906A (en) Selective mmp-13 inhibitors
CL2004001579A1 (es) Composicion farmaceutica que comprende un analogo de somatostatina y acido tartarico, donde la composicion tiene el ph regulado entre 4 y 4,5 y el compuesto activo es l ciclo[{4-(nh2-c2h4-nh-cp-o)pro}-phg-dtrp-lys-tyr(4-bzl)-phe]; y su uso para prepa
SE0100873D0 (sv) Method of treatment
SE0103476D0 (sv) New use
ATE293667T1 (de) Tensidhaltige reinigungsmittel mit enzym- inhibitoren
DE602006018833D1 (de) Körperpflegezusammensetzungen enthaltend Alkylphosphattenside und ausgewählte Schwachsäure Hilfsmittel
EA200601818A1 (ru) Фармацевтический препарат, содержащий дроспиренон, для нанесения на поверхность кожи
ATE373468T1 (de) Orales spray gegen erkältungssymptome und deren dauer
JP2004155748A (ja) システアミンパーマ液の第２剤